Quantcast
Last updated on April 24, 2014 at 21:24 EDT

Latest Triple-negative breast cancer Stories

2013-10-21 08:28:36

ROCKVILLE, Md., Oct. 21, 2013 /PRNewswire/ -- EntreMed, Inc. (NASDAQ:ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers, announced today the presentation of preclinical data from a study to assess the role of p53 family tumor suppressors in mediating response to ENMD-2076 in triple-negative breast cancer (TNBC). The study was led by Dr. Jennifer R. Diamond of University of Colorado and the results were presented at the...

2013-10-11 12:24:58

Metastatic breast cancer causes 40,000 deaths each year and an estimated 155,000 women and men are living with metastatic breast cancer in the U.S. NEW YORK, Oct. 11, 2013 /PRNewswire-USNewswire/ -- This October, between the survivor celebrations and screening messages, you will be missing some important facts about breast cancer: -- This year, 39,620 women and 410 men will die of metastatic breast cancer in the United States, a number that has changed little over the past 40...

2013-10-01 23:00:50

A major Department of Defense grant to researchers Jennifer Richer, PhD, and Anthony Elias, MD, at the University of Colorado Cancer Center aids development of drugs that target androgen receptors as a driver of breast cancer. AURORA, Colo. (PRWEB) October 01, 2013 A major Department of Defense grant to researchers Jennifer Richer, PhD, and Anthony Elias, MD, at the University of Colorado Cancer Center aids development of drugs that target androgen receptors as a driver of breast cancer....

2013-08-12 12:27:34

BOSTON, Aug. 12, 2013 /PRNewswire-USNewswire/ -- In a new paper in Cancer Cell, a team led by Judy Lieberman, PhD, of Boston Children's Hospital's Program in Cellular and Molecular Medicine reports "triple-negative" breast cancers may be vulnerable to drugs that attack the proteasome. This cellular structure acts as the cell's waste disposal, breaking down damaged or unneeded proteins. These cancers, which lack the three major therapeutic markers for breast cancer--the estrogen,...

2013-07-29 08:25:39

ROCKVILLE, Md., July 29, 2013 /PRNewswire/ -- EntreMed, Inc. (NASDAQ: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers, announced today that it has initiated a crossover bioavailability and food effect study of ENMD-2076. The study is a single-blind, randomized, single-dose, crossover study with a food effect arm to investigate the safety and relative bioavailability of two dosage forms of ENMD-2076 administered as...

2013-07-26 16:20:02

Singapore, July 27, 2013 - (ACN Newswire) - Scientists at A*STAR's Genome Institute of Singapore (GIS) led in a study that has identified genes that are potential targets for therapeutic drugs against aggressive breast cancer. These findings were reported in the July 2013 issue of PNAS. Out of the 1.5 million women diagnosed with breast cancer in the world annually, nearly one in seven of these is classified as triple negative. Patients with triple- negative breast cancer (TNBC) have tumours...

New Compound BH3 Mimetics Future Of Breast Cancer Treatment
2013-07-09 09:40:18

[ Watch the Video: New Anti-Cancer Compound Shows Promise For Breast Cancer ] Rebekah Eliason for redOrbit.com - Your Universe Online Scientists from Melbourne, Australia recently discovered compounds currently being researched to treat leukemia may also be effective in treating the most common form of breast cancer. Researchers found a group of anti-cancer compounds known as BH3-mimetics are effective for treating estrogen receptor-positive (ER-positive) forms of breast cancers when...

2013-06-27 08:29:19

ROCKVILLE, Md., June 27, 2013 /PRNewswire/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers, announced today that it has submitted a new drug global clinical trial application with the China Food and Drug Administration (CFDA) for its proprietary oncology drug candidate, ENMD-2076. The purpose of the application is to expand the Company's Phase 2 clinical trial in advanced/metastatic sarcoma...

2013-06-25 23:27:40

Centrose announces the issuance of the first patent that covers a new class of antibody drug conjugates. The patent covers a new cancer drug candidate for treating metastatic drug resistant cancers. Madison, Wisconsin (PRWEB) June 25, 2013 Centrose, a company focused on developing safer and more effective therapies that improve patient health, announced today that the United States Patent and Trademark Office (USPTO) issued Centrose its first Extracellular Drug Conjugate (EDC) Patent....

2013-06-03 23:14:07

The HER2 growth-factor gene is known to be over-active in breast and gastro-esophageal cancers. But now, irregularities in the genes ℠s expression – among them mutations, amplifications, substitutions, and translocations – have been found in 14 different advanced solid tumors. Chicago, Illinois (PRWEB) June 03, 2013 The HER2 growth-factor gene is known to be over-active in breast and gastro-esophageal cancers. But now, irregularities in the genes ℠s expression...